182 related articles for article (PubMed ID: 36797358)
1. Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer.
Asami Y; Kobayashi Kato M; Hiranuma K; Matsuda M; Shimada Y; Ishikawa M; Koyama T; Komatsu M; Hamamoto R; Nagashima M; Terao Y; Itakura A; Kohno T; Sekizawa A; Matsumoto K; Kato T; Shiraishi K; Yoshida H
Br J Cancer; 2023 Apr; 128(8):1582-1591. PubMed ID: 36797358
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
3. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
[TBL] [Abstract][Full Text] [Related]
4. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
5. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
6.
De Leo A; de Biase D; Lenzi J; Barbero G; Turchetti D; Grillini M; Ravegnini G; Angelini S; Zamagni C; Coluccelli S; Dondi G; De Iaco P; Perrone AM; Tallini G; Santini D; Ceccarelli C
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668727
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract][Full Text] [Related]
8. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
[TBL] [Abstract][Full Text] [Related]
11. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
Siegenthaler F; Lindemann K; Epstein E; Rau TT; Nastic D; Ghaderi M; Rydberg F; Mueller MD; Carlson J; Imboden S
Gynecol Oncol; 2022 May; 165(2):230-238. PubMed ID: 35277281
[TBL] [Abstract][Full Text] [Related]
12. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
Lindemann K; Kildal W; Kleppe A; Tobin KAR; Pradhan M; Isaksen MX; Vlatkovic L; Danielsen HE; Kristensen GB; Askautrud HA
Eur J Cancer; 2024 Mar; 200():113584. PubMed ID: 38330767
[TBL] [Abstract][Full Text] [Related]
13. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
[TBL] [Abstract][Full Text] [Related]
15. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
17. The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification.
Yamazaki H; Asano H; Hatanaka KC; Matsuoka R; Konno Y; Matsuno Y; Hatanaka Y; Watari H
Cancer Sci; 2022 Sep; 113(9):3134-3147. PubMed ID: 35707843
[TBL] [Abstract][Full Text] [Related]
18. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer.
Kolehmainen A; Pasanen A; Tuomi T; Koivisto-Korander R; Bützow R; Loukovaara M
PLoS One; 2020; 15(11):e0242733. PubMed ID: 33232359
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of transcription factor
Onoprienko A; Hofstetter G; Muellauer L; Dorittke T; Polterauer S; Grimm C; Bartl T
Int J Gynecol Cancer; 2024 Mar; ():. PubMed ID: 38508586
[TBL] [Abstract][Full Text] [Related]
20. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E; Bosse T; Nout RA; MacKay HJ; Church DN; Nijman HW; Leary A; Edmondson RJ; Powell ME; Crosbie EJ; Kitchener HC; Mileshkin L; Pollock PM; Smit VT; Creutzberg CL
Mod Pathol; 2015 Jun; 28(6):836-44. PubMed ID: 25720322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]